

Coronary Restenosis

[View the current Coronary Restenosis InDepth page on BioPortfolio.com \(PDF\)](#)

(http://www.bioportfolio.com/indepth/Coronary_Restenosis.html) - Regularly Updated.



Recent Publications on Coronary Restenosis:

- [Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions.](#)
BACKGROUND: The TAXUS II trial was designed to evaluate the safety and... 18th November, 2009
Cardiology Practice and Hospital, Am Isarkanal 36, D-81379 Munich,- Circulation. 2009 Oct 13;120(15):1498-504. Epub 2009 Sep 28. ([DOI Direct Link](#))
- [Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics](#)
Various systemic pharmacological approaches have been evaluated to reduce... 18th November, 2009
Universite de Liege, Service de diabetologie, nutrition et maladies- Rev Med Suisse. 2009 Aug 26;5(214):1638-43.
- [Stuck in the wrong place.](#)
The study included retrospective analysis of the results of treatment in... 11th November, 2009
- Am J Med. 2009 Nov;122(11):e7-8. ([DOI Direct Link](#))
- [Analysis of immediate and mid-term outcomes of surgical and endoscopic treatment of patients with coronary heart disease and multiple lesions of coronary arteries](#)
The study included retrospective analysis of the results of treatment in... 4th November, 2009
- Klin Med (Mosk). 2009;87(9):15-22.
- [Elevated levels of inflammation reactive factors as a sign of restenosis after stenting](#)
The study included retrospective analysis of the results of treatment in... 29th October, 2009
- Kardiol Pol. 2009 Jun;67(6):631.
- [Optical coherence tomography \(OCT\) in secondary revascularisation: stent and graft assessment.](#)
Optical coherence tomography is a recently introduced intracoronary... 24th October, 2009
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.- EuroIntervention. 2009 May;5 Suppl D:D93-D100.
- [Drug-eluting stents: a study of international practice.](#)
OBJECTIVE: We aimed to analyze trends in drug-eluting stents (DES) use in... 21st October, 2009
Department of Public Health and Health Policy, University of Glasgow,- Am Heart J. 2009 Oct;158(4):576-84. ([DOI Direct Link](#))
- [Design and rationale of the TRI-stent adjudication study \(TRIAS\) program.](#)
BACKGROUND: In the treatment of coronary artery disease, a "pro-healing"... 21st October, 2009
Department of Cardiology, Academic Medical Center, University of- Am Heart J. 2009 Oct;158(4):527-532.e1. ([DOI Direct Link](#))
- [The high cost of nonadherence after percutaneous coronary intervention--can health care reform solve this problem?](#)

- BACKGROUND: In the treatment of coronary artery disease, a "pro-healing"...*21st October, 2009
- Am Heart J. 2009 Oct;158(4):506-8. Epub 2009 Aug 22. ([DOI Direct Link](#))
- [Are we sure we have taken the best from clopidogrel?](#)
*BACKGROUND: In the treatment of coronary artery disease, a "pro-healing"...*21st October, 2009
- Am Heart J. 2009 Oct;158(4):e59. Epub 2009 Aug 26. ([DOI Direct Link](#))
 - [A simple ECG marker for the detection of coronary restenosis after successful coronary angioplasty.](#)
*BACKGROUND: The dynamic nature of QT dispersion (QTd) and the absence of...*17th October, 2009
Epidemiological Cardiology Research Center, Department of Epidemiology and- Intern Med.
2009;48(20):1793-8. Epub 2009 Oct 15.
 - [Lack of Association Between the Cholesteryl Ester Transfer Protein Gene--Tag1B Polymorphism and Coronary Restenosis Following Percutaneous Transluminal Coronary Angioplasty and Stenting: A Pilot Study.](#)
*Background: The most widely studied variation at the cholesteryl ester...*10th October, 2009
- Angiology. 2009 Oct 8. ([DOI Direct Link](#))
 - [Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS \(Failure in Left Main Study\).](#)
*OBJECTIVES: This study sought to retrospectively appraise the incidence...*9th October, 2009
University of Turin, Italy.- J Am Coll Cardiol. 2009 Sep 22;54(13):1131-6. ([DOI Direct Link](#))
 - [Genetic susceptibility to restenosis: role of bone marrow cells and inflammatory response.](#)
*OBJECTIVES: This study sought to retrospectively appraise the incidence...*30th September, 2009
- Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1407-8. ([DOI Direct Link](#))
 - [Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?](#)
*Type 2 diabetes is associated with substantially increased cardiovascular...*17th September, 2009
Outpatient Clinic of Obesity, Diabetes and Metabolism at the Second- Curr Pharm Des.
2009;15(27):3179-92.

Coronary Restenosis Patents:



- 7311727- [Encased stent](#)
- 7378105- [Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens](#)
- 7390822- [Substituted 4-phenyl-4-\[1H-imidazol-2-yl\]-piperidine derivatives for reducing ischaemic damage](#)
- 7396358- [Device and method for converting a balloon catheter into a cutting balloon catheter](#)
- 7396821- [Intravascular delivery of nucleic acid](#)
- 7399480- [Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices](#)
- 7405277- [Antibodies against monocyte chemotactic proteins](#)
- 7413728- [Immune modulator](#)
- 7419678- [Coated medical devices for the prevention and treatment of vascular disease](#)
- 7420000- [Amino phosphonate and amino bis-phosphonate derivatives](#)
- 7438910- [Therapeutic human anti-IL1-R1 monoclonal antibody](#)
- 7371862- [Azaindolydene derivatives as kinase inhibitors, process for their preparation and](#)

[pharmaceutical compositions comprising them](#)

- [7368248- Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases](#)
- [7364736- Antibodies to OPGL](#)
- [7318944- Extrusion process for coating stents](#)
- [7318945- Laminated drug-polymer coated stent having dipped layers](#)
- [7332337- Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells](#)
- [7332493- Substituted bicyclic derivatives for the treatment of abnormal cell growth](#)
- [7332579- Antibodies to human ErbB4](#)
- [7351711- Tricyclic indanyls as integrin inhibitors](#)
- [7351712- Pyrimidine derivatives for the treatment of abnormal cell growth](#)
- [7357942- Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens](#)
- [7358088- Peptides and compositions which modulate apoptosis](#)
- [7364586- C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis](#)
- [7455853- Medical devices containing rapamycin analogs](#)
- [7462153- Method and system for modeling cardiovascular disease using a probability regression model](#)
- [7575632- Reflowed drug-polymer coated stent and method thereof](#)
- [7582602- Hirulog-like peptide and gene therapy](#)
- [7582742- Method of treating or preventing an IL-1 related disease or condition](#)
- [7585507- Nucleic acid molecules and polypeptides for immune modulation](#)
- [7585869- Substituted heterocycles for the treatment of abnormal cell growth](#)
- [7589059- Delivery of molecules and complexes to mammalian cells in vivo](#)
- [7595325- Substituted pyrrolo\[2,3-d\]pyrimidine derivatives useful in cancer treatment](#)
- [7597888- Glycoprotein VI and uses thereof](#)
- [7604700- Stent mandrel fixture and method for selectively coating surfaces of a stent](#)
- [7612094- Tri-substituted heteroaryls and methods of making and using the same](#)
- [7569387- Antibody to TNF receptor-like molecules](#)
- [7566772- Antibodies against interleukin-1.beta.](#)
- [7566566- Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins](#)
- [7465298- Methods and systems for delivering liquid substances to tissues surrounding body lumens](#)
- [7479369- Use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases](#)
- [7482013- Albumin fusion proteins](#)
- [7507722- Intravascular delivery of nucleic acid](#)
- [7531166- IL-1.beta. binding antibodies and fragments thereof](#)
- [7547301- Device and method to slow or stop the heart temporarily](#)
- [7547680- Benzimidazole derivatives and medical uses thereof](#)
- [7550300- Prediction of bare metal stent restenosis](#)
- [7553377- Apparatus and method for electrostatic coating of an abluminal stent surface](#)
- [7563324- System and method for coating an implantable medical device](#)
- [7619066- IL-1ra variants](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

